The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (24 analysts) rates it none, with a mean price target of $360.
Travelers Companies (The)
TRV · a US exchange · USD · Market cap $79.7B · 34,000 employees
The Travelers Companies, Inc., through its subsidiaries, provides a range of commercial and personal property, and casualty insurance products and services to businesses, government units, associations, and individuals i…
FAIL · Does not pass the screenScreen close, 2026-09-18 · not a live quote
Last reviewed 4 days ago
Screened 2026-09-18 · the tape above runs as of 11:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 374.62 against the desk's fair-value range, base estimate 315.69, over the last year.
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
Travelers Companies (The) holds its Accumulation at $374.62. Consolidating, no directional conviction, held for 2 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 2 days |
| Price at the screen | $374.62 |
| Valuation | 10.07 trailing · 12.40 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.45 |
Five Screens, Shown in Full
Does not pass. Business activity screen
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Business activity: Financials sector | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads AVOID: it trades above our $315.69 fair value estimate, moderate competitive moat, 0.30% revenue growth.
Fair value range in USD, drawn from the 2026-09-18 screen. The gold marker is the market price at the same screen. The price runs 15.7% above the base estimate.
Third-party analyst targets: 24 covering, consensus None. The average target sits −4% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-18 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsInsurer priced for growth it cannot deliver
Picture a homeowner paying premiums every month for the promise of cover when disaster strikes. Travelers has built a solid book of that business across the United States, yet revenue has flatlined and the shares now trade at 369 dollars against a fair value nearer 301 dollars.
We pass for two clear reasons. The forward multiple of 12.7 times offers little margin when growth sits at zero, while the ethical screen flags the business on activity grounds. A 27 percent return on equity and 17 percent profit margin look respectable, but they do not offset the valuation gap or the ethical breach.
The stock may drift with the broader market and analyst targets hover around 340 dollars, yet paying a premium for no growth while failing a basic values check is not a combination we accept. Analysis, not advice.
| Forward P/E | 12.4xexpensive even after accounting for its growth |
| Trailing P/E | 10.1xreasonably valued |
| EPS, trailing | 37.19 |
| EPS, forward | 30.21 |
| Revenue growth | +0.3%slow but positive growth |
| Profit margin | 17.0%healthy profit margins |
| Return on equity | 26.5%an exceptional return on shareholder capital |
| FCF yield | 19.37% |
| Dividend yield | 168.00% |
| Debt to equity | 0.27minimal debt: a conservative balance sheet |
| Current ratio | 0.32below 1: short-term bills exceed liquid assets |
| Beta | 0.45barely tracks the market's swings |
| Short interest, float | 0.03% |
| 52-week range | 252.26 - 398.70 |
| Moat | MODERATE |
| Market cap | $79.7B |
| Employees | 34,000 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeTRV trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 26.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it hold, with a mean price target of $313.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 17%. Our forward projection puts the odds of a 10% gain over the next month near 17%. The street (23 analysts) rates it hold, with a mean price target of $313.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- PRU's Investment Income Poised to Benefit From Higher Rates Zacks · 4d ago
- New Strong Buy Stocks for September 18th Zacks · 4d ago
- Best Income Stocks to Buy for September 18th Zacks · 4d ago
- Fed Reverses Course With First Rate Hike Since 2023: 3 Insurers to Buy Zacks · 5d ago
- SIGI's Investment Income Boosts Earnings Despite Underwriting Pressure Zacks · 5d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-30 | KESS AVROHOM J | Officer | 1,000 | · | |
| 2026-04-28 | HEYMAN WILLIAM H | Officer | 1,557 | $294,289 | |
| 2026-04-28 | KESS AVROHOM J | Officer | 27,686 | $3,899,573 | |
| 2026-04-28 | HEYMAN WILLIAM H | Officer | 1,557 | $483,670 | |
| 2026-04-28 | KESS AVROHOM J | Officer | 6,735 | $2,079,640 | |
| 2026-04-23 | THOMSEN LAURIE J | Director | 631 | · | |
| 2026-04-20 | KURTZMAN DIANE | Officer | 1,387 | $183,888 | |
| 2026-04-20 | KLEIN MICHAEL FREDERICK | Officer | 10,000 | $1,325,800 | |
| 2026-04-20 | KESS AVROHOM J | Officer | 2,125 | · | |
| 2026-04-20 | KLEIN MICHAEL FREDERICK | Officer | 10,000 | $3,037,691 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-07-02 | John Boozman | Republican | sell | 1K–15K |
| 2026-07-02 | John Boozman | Republican | sell | 1K–15K |
| 2026-03-27 | Alan Armstrong | Republican | buy | 1K–15K |
| 2024-10-29 | Tommy Tuberville | Republican | sell | 15K–50K |
| 2024-10-29 | Tommy Tuberville | Republican | sell | 15K–50K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $297.13 | +2.1% | · | $1,021 | +2.1% |
| 2 months | $297.26 | +2.1% | · | $1,021 | +2.1% |
| 3 months | $302.01 | +0.5% | · | $1,005 | +0.5% |
| 6 months | $281.85 | +7.6% | $1.10 | $1,080 | +8.0% |
| 1 year | $259.96 | +16.7% | $4.40 | $1,184 | +18.4% |
| 2 years | $207.05 | +46.5% | $8.60 | $1,507 | +50.7% |
| 3 years | $167.11 | +81.5% | $11.60 | $1,885 | +88.5% |
| 5 years | $140.76 | +115.5% | $18.96 | $2,290 | +129.0% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever TRV does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.